Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3

Abstract

In the 2022 series, we summarized the major clinical research advances in gynecologiconcology based on communications at the conference of Asian Society of GynecologicOncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-updata, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall sur vival (OS) issues withPARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy,and antibody-drug conjugate; 2) Cer vical cancer: surger y in early stage disease, therapyfor locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpuscancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitorof nuclear export. A special note was made on the withdrawal of PARP inhibitor from themarket for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4and SOLO-3 due to concerns of increased risk of death.